Physician profile
Eri Sugino
NPI 1962506907
$6,142.02
in general payments reported to CMS, 2019-2025
28 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $465 · 2021: $851 · 2022: $813 · 2023: $1,001 · 2024: $1,178 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,459.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $967.82 | 2021-2025 | Photrexa Viscous and Photrexa, Idosetr, Istent Infinite |
| Bausch & Lomb Americas INC. | $897.48 | 2022-2025 | Infuse, Alden Scleral Zenlens, Infuse Multifocal |
| Aerie Pharmaceuticals, INC. | $628.74 | 2019-2021 | |
| Alcon Vision LLC | $586.45 | 2019-2025 | Total30, Rocklatan, Clareon |
| Sun Pharmaceutical Industries INC. | $537.55 | 2019-2025 | Cequa |
| Dompe US, INC. | $451.70 | 2020-2025 | Oxervate |
| Abbvie INC. | $283.05 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $277.75 | 2019-2023 | |
| Johnson & Johnson Vision Care, INC. | $221.20 | 2022-2025 | Acuvue |
| Amgen INC. | $203.95 | 2024-2025 | Tepezza |
| Genentech USA, INC. | $157.13 | 2022-2023 | Vabysmo |
| New World Medical,INC. | $144.98 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $127.47 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $124.22 | 2022-2025 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $94.18 | 2021-2025 | Myday Contact Lens |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $77.03 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $67.39 | 2020-2021 | |
| Sight Sciences, INC. | $38.16 | 2021-2025 | Tearcare System |
| Horizon Therapeutics Plc | $37.59 | 2023 | Tepezza |
| Rxsight INC | $36.35 | 2024-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Regeneron Healthcare Solutions, INC. | $26.28 | 2025 | Eylea Hd |
| Mallinckrodt Enterprises LLC | $26.14 | 2019 | |
| Biotissue Holdings INC. | $25.00 | 2025 | |
| Kala Pharmaceuticals, INC. | $24.84 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $23.99 | 2021 | |
| Beaver-Visitec International, INC. | $21.66 | 2025 | |
| Shire North American Group INC | $20.77 | 2019 | |
| Allergan, INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eri Sugino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.